Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Pricing of HPV vaccines in European tender-based settings.

Qendri V, Bogaards JA, Berkhof J.

Eur J Health Econ. 2018 Jul 26. doi: 10.1007/s10198-018-0996-9. [Epub ahead of print]

PMID:
30051152
2.

Three-tiered score for Ki-67 and p16ink4a improves accuracy and reproducibility of grading CIN lesions.

van Zummeren M, Leeman A, Kremer WW, Bleeker MCG, Jenkins D, van de Sandt M, Heideman DAM, Steenbergen R, Snijders PJF, Quint WGV, Berkhof J, Meijer CJLM.

J Clin Pathol. 2018 Jul 16. pii: jclinpath-2018-205271. doi: 10.1136/jclinpath-2018-205271. [Epub ahead of print]

3.

Human papillomavirus (HPV) prevalence and associated risk factors in women from Curaçao.

Hooi DJ, Lissenberg-Witte BI, Kenter G, de Koning MNC, Gomes Bravio I, Ardts K, Kleinmoedig S, Benita E, Pinedo HM, Berkhof J, Quint WGV, Meijer CJLM.

PLoS One. 2018 Jul 13;13(7):e0199624. doi: 10.1371/journal.pone.0199624. eCollection 2018.

4.

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.

Kaspers GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, Lopez-Yurda M, Berkhof J, Cloos J, de Haas V, Mathôt RA, Attarbaschi A, Baruchel A, de Bont ES, Fagioli F, Rössig C, Klingebiel T, De Moerloose B, Nelken B, Palumbo G, Reinhardt D, Rohrlich PS, Simon P, von Stackelberg A, Zwaan CM.

Br J Haematol. 2018 May;181(4):523-527. doi: 10.1111/bjh.15233. Epub 2018 Apr 20.

PMID:
29676440
5.

Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.

De Strooper LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, Snijders PJF, Meijer CJLM, Heideman DAM.

Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539. [Epub ahead of print]

PMID:
29663363
6.

Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples.

Verlaat W, Snoek BC, Heideman DAM, Wilting SM, Snijders PJF, Novianti PW, van Splunter AP, Peeters CFW, van Trommel NE, Massuger LFAG, Bekkers RLM, Melchers WJG, van Kemenade FJ, Berkhof J, van de Wiel MA, Meijer CJLM, Steenbergen RDM.

Clin Cancer Res. 2018 Jul 15;24(14):3456-3464. doi: 10.1158/1078-0432.CCR-17-3615. Epub 2018 Apr 9.

PMID:
29632006
7.

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C.

Lancet Public Health. 2016 Nov;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9. Epub 2016 Sep 27. Review.

8.

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Dec 1;74(12):1481-1491. doi: 10.1001/jamaneurol.2017.2712.

PMID:
29049480
9.

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.

Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer CJLM, Berkhof J.

Br J Cancer. 2017 Nov 7;117(10):1557-1561. doi: 10.1038/bjc.2017.309. Epub 2017 Sep 7.

PMID:
28881359
10.

Identification of patients with cancer with a high risk to develop delirium.

Neefjes ECW, van der Vorst MJDL, Verdegaal BATT, Beekman ATF, Berkhof J, Verheul HMW.

Cancer Med. 2017 Aug;6(8):1861-1870. doi: 10.1002/cam4.1106. Epub 2017 Jul 7.

11.

Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.

Veldhuijzen NJ, Polman NJ, Snijders PJF, Meijer CJLM, Berkhof J.

Int J Cancer. 2017 Oct 15;141(8):1551-1560. doi: 10.1002/ijc.30865. Epub 2017 Jul 18.

PMID:
28670823
12.

An EM algorithm for nonparametric estimation of the cumulative incidence function from repeated imperfect test results.

Witte BI, Berkhof J, Jonker MA.

Stat Med. 2017 Sep 20;36(21):3412-3421. doi: 10.1002/sim.7373. Epub 2017 Jun 20.

PMID:
28631295
13.

Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands.

Qendri V, Bogaards JA, Berkhof J.

J Infect Dis. 2017 Jul 15;216(2):210-219. doi: 10.1093/infdis/jix272.

PMID:
28586466
14.

Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing.

McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA.

Cancer Causes Control. 2017 Mar;28(3):203-214. doi: 10.1007/s10552-017-0870-6. Epub 2017 Feb 17.

PMID:
28213874
15.

Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.

Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, Farley C, Monsonego J, Franceschi S.

Int J Cancer. 2017 May 15;140(10):2192-2200. doi: 10.1002/ijc.30579. Epub 2017 Jan 11. Review.

16.

Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.

Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J.

BMJ. 2016 Oct 4;355:i4924. doi: 10.1136/bmj.i4924. Erratum in: BMJ. 2016 Oct 27;355:i5782.

17.

Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.

Polman NJ, Uijterwaal MH, Witte BI, Berkhof J, van Kemenade FJ, Spruijt JW, van Baal WM, Graziosi PG, van Dijken DK, Verheijen RH, Helmerhorst TJ, Steenbergen RD, Heideman DA, Ridder R, Snijders PJ, Meijer CJ.

Int J Cancer. 2017 Jan 15;140(2):423-430. doi: 10.1002/ijc.30449. Epub 2016 Oct 11.

18.

Resilience of a FIT screening programme against screening fatigue: a modelling study.

Greuter MJ, Berkhof J, Canfell K, Lew JB, Dekker E, Coupé VM.

BMC Public Health. 2016 Sep 22;16(1):1009.

19.

A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization.

Vink MA, Berkhof J, van de Kassteele J, van Boven M, Bogaards JA.

PLoS One. 2016 Aug 18;11(8):e0161109. doi: 10.1371/journal.pone.0161109. eCollection 2016.

20.

Management of high-risk HPV-positive women for detection of cervical (pre)cancer.

Luttmer R, De Strooper LM, Steenbergen RD, Berkhof J, Snijders PJ, Heideman DA, Meijer CJ.

Expert Rev Mol Diagn. 2016 Sep;16(9):961-74. doi: 10.1080/14737159.2016.1217157. Epub 2016 Aug 5. Review.

PMID:
27459506
21.

Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN.

Uijterwaal MH, van Zummeren M, Kocken M, Luttmer R, Berkhof J, Witte BI, van Baal WM, Graziosi GCM, Verheijen RHM, Helmerhorst TJM, van Dijken DKE, Spruijt JWM, van Kemenade FJ, Fransen-Daalmeijer N, Bekker-Lettink M, Heideman DAM, Snijders PJF, Steenbergen RDM, Meijer CJLM.

Gynecol Oncol. 2016 Oct;143(1):135-142. doi: 10.1016/j.ygyno.2016.07.089. Epub 2016 Jul 16.

PMID:
27430395
22.

FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.

Luttmer R, De Strooper LM, Dijkstra MG, Berkhof J, Snijders PJ, Steenbergen RD, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, van Baal WM, Graziosi PG, Quint WG, Spruijt JW, van Dijken DK, Heideman DA, Meijer CJ.

Br J Cancer. 2016 Aug 23;115(5):579-87. doi: 10.1038/bjc.2016.200. Epub 2016 Jul 14.

23.

Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma.

Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J.

Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1224-30. doi: 10.1158/1055-9965.EPI-16-0019. Epub 2016 Jun 2.

24.

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, Stoker J, Coupé VM.

Br J Radiol. 2016 Jul;89(1063):20150910. doi: 10.1259/bjr.20150910. Epub 2016 May 19.

25.

p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.

Luttmer R, Dijkstra MG, Snijders PJ, Berkhof J, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, van Baal WM, Graziosi PG, Quint WG, Spruijt JW, van Dijken DK, Heideman DA, Meijer CJ.

Mod Pathol. 2016 Aug;29(8):870-8. doi: 10.1038/modpathol.2016.80. Epub 2016 May 6.

26.

Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.

De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, Bosgraaf RP, Bekkers RLM, Massuger LFAG, Melchers WJG, Steenbergen RDM, Snijders PJF, Meijer CJLM, Heideman DAM.

Gynecol Oncol. 2016 May;141(2):341-347. doi: 10.1016/j.ygyno.2016.02.012. Epub 2016 Mar 3.

27.

Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.

Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, Verheul HM.

J Clin Oncol. 2016 Apr 20;34(12):1339-44. doi: 10.1200/JCO.2015.63.6043. Epub 2016 Feb 22.

PMID:
26903572
28.

Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.

Hesselink AT, Sahli R, Berkhof J, Snijders PJ, van der Salm ML, Agard D, Bleeker MC, Heideman DA.

J Clin Virol. 2016 Mar;76:36-9. doi: 10.1016/j.jcv.2016.01.009. Epub 2016 Jan 15.

29.

Presence of human papillomavirus in semen in relation to semen quality.

Luttmer R, Dijkstra MG, Snijders PJ, Hompes PG, Pronk DT, Hubeek I, Berkhof J, Heideman DA, Meijer CJ.

Hum Reprod. 2016 Feb;31(2):280-6. doi: 10.1093/humrep/dev317. Epub 2016 Jan 2.

PMID:
26724799
30.

Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway.

Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, Dekker E, Meijer GA, Coupé VM.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):135-44. doi: 10.1158/1055-9965.EPI-15-0592. Epub 2015 Nov 23.

31.

The performance of Dynamic Spectral Imaging colposcopy depends on indication for referrals.

Louwers JA, Zaal A, Kocken M, Berkhof J, Papagiannakis E, Snijders PJ, Meijer CJ, Verheijen RH.

Gynecol Oncol. 2015 Dec;139(3):452-7. doi: 10.1016/j.ygyno.2015.10.009. Epub 2015 Oct 22.

PMID:
26475960
32.

Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion.

Rossi PG, Ronco G, Dillner J, Elfström KM, Snijders PJ, Arbyn M, Berkhof J, Carozzi F, Del Mistro A, De Sanjosè S, Bosch X, Petry KU, Poljak M, Naldoni C, Meijer CJ; Comparing Health Services Interventions for the Prevention of HPV-Related Cancer Consortium; New Technologies for Cervical Cancer Group.

Cancer Cytopathol. 2016 Jan;124(1):66-7. doi: 10.1002/cncy.21622. Epub 2015 Sep 10. No abstract available.

33.

Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).

Luttmer R, De Strooper LM, Berkhof J, Snijders PJ, Dijkstra MG, Uijterwaal MH, Steenbergen RD, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, Van Baal WM, Graziosi PG, Quint WG, Heideman DA, Meijer CJ.

Int J Cancer. 2016 Feb 15;138(4):992-1002. doi: 10.1002/ijc.29824. Epub 2015 Sep 14.

34.

Presence of human papillomavirus in semen of healthy men is firmly associated with HPV infections of the penile epithelium.

Luttmer R, Dijkstra MG, Snijders PJF, Jordanova ES, King AJ, Pronk DTM, Foresta C, Garolla A, Hompes PGA, Berkhof J, Bleeker MCG, Doorbar J, Heideman DAM, Meijer CJLM.

Fertil Steril. 2015 Oct;104(4):838-844.e8. doi: 10.1016/j.fertnstert.2015.06.028. Epub 2015 Jul 23.

PMID:
26211884
35.

Predictive Value of C-Reactive Protein for Major Complications after Major Abdominal Surgery: A Systematic Review and Pooled-Analysis.

Straatman J, Harmsen AM, Cuesta MA, Berkhof J, Jansma EP, van der Peet DL.

PLoS One. 2015 Jul 15;10(7):e0132995. doi: 10.1371/journal.pone.0132995. eCollection 2015. Review.

36.

Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.

Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J.

BMJ. 2015 May 12;350:h2016. doi: 10.1136/bmj.h2016.

37.

Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.

Luttmer R, Berkhof J, Dijkstra MG, van Kemenade FJ, Snijders PJ, Heideman DA, Meijer CJ.

J Clin Virol. 2015 Jun;67:59-66. doi: 10.1016/j.jcv.2015.04.004. Epub 2015 Apr 7.

PMID:
25959161
38.

Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, Poljak M.

Clin Microbiol Infect. 2015 Sep;21(9):817-26. doi: 10.1016/j.cmi.2015.04.015. Epub 2015 May 1. Review.

39.

The effect of individualized nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: a randomized controlled trial protocol.

van der Werf A, Blauwhoff-Buskermolen S, Langius JA, Berkhof J, Verheul HM, de van der Schueren MA.

BMC Cancer. 2015 Mar 5;15:98. doi: 10.1186/s12885-015-1092-5.

40.

A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma.

de Baaij LR, Berkhof J, van de Water JM, Sieniawski MK, Radersma M, Verbeek WH, Visser OJ, Oudejans JJ, Meijer CJ, Mulder CJ, Lennard AL, Cillessen SA.

Clin Cancer Res. 2015 Jul 1;21(13):3013-9. doi: 10.1158/1078-0432.CCR-14-2195. Epub 2015 Mar 16.

41.

Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.

Uijterwaal MH, Polman NJ, Van Kemenade FJ, Van Den Haselkamp S, Witte BI, Rijkaart D, Berkhof J, Snijders PJ, Meijer CJ.

Cancer Prev Res (Phila). 2015 Jun;8(6):502-8. doi: 10.1158/1940-6207.CAPR-14-0409. Epub 2015 Mar 16.

42.

Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes.

Verhoef VM, van Kemenade FJ, Rozendaal L, Heideman DA, Bosgraaf RP, Hesselink AT, Melchers WJ, Massuger LF, Bekkers RL, Steenbergen RD, Berkhof J, Snijders PJ, Meijer CJ.

Gynecol Oncol. 2015 Apr;137(1):55-9. doi: 10.1016/j.ygyno.2015.01.550. Epub 2015 Feb 8.

PMID:
25667975
43.

Risk factors for poor neonatal adaptation after exposure to antidepressants in utero.

Kieviet N, Hoppenbrouwers C, Dolman KM, Berkhof J, Wennink H, Honig A.

Acta Paediatr. 2015 Apr;104(4):384-91. doi: 10.1111/apa.12921. Epub 2015 Feb 3.

PMID:
25559357
44.

Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?

Vink MA, Bogaards JA, Meijer CJ, Berkhof J.

Int J Cancer. 2015 Jul 15;137(2):420-7. doi: 10.1002/ijc.29381. Epub 2014 Dec 17. Erratum in: Int J Cancer. 2018 Apr 15;142(8):E4.

45.

The Potential of (TARGETED) MR Colonography as a Screening Tool for Colorectal Cancer: A Cost-Effectiveness Analysis.

Greuter MJ, Demirel E, Berkhof J, Fijneman RJ, Stoker J, Meijer GA, Coupé VM.

Value Health. 2014 Nov;17(7):A631-2. doi: 10.1016/j.jval.2014.08.2260. Epub 2014 Oct 26. No abstract available.

46.

Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway.

Greuter MJ, Lew JB, Berkhof J, Canfell K, Dekker E, Meijer GA, Coupe VM.

Value Health. 2014 Nov;17(7):A323. doi: 10.1016/j.jval.2014.08.565. Epub 2014 Oct 26. No abstract available.

47.

Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?

van der Marel J, Berkhof J, Ordi J, Torné A, Del Pino M, van Baars R, Schiffman M, Wentzensen N, Jenkins D, Quint WG.

Am J Surg Pathol. 2015 Apr;39(4):496-504. doi: 10.1097/PAS.0000000000000342.

PMID:
25353286
48.

Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.

Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GA, Ridder R, Snijders PJ, Meijer CJ.

Int J Cancer. 2015 May 15;136(10):2361-8. doi: 10.1002/ijc.29290. Epub 2014 Nov 6.

49.

The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials.

Veldhuijzen NJ, Berkhof J, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Snijders PJ, Meijer CJ, Ronco G.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):111-8. doi: 10.1158/1055-9965.EPI-14-0628. Epub 2014 Oct 9.

50.

Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions.

De Strooper LM, Meijer CJ, Berkhof J, Hesselink AT, Snijders PJ, Steenbergen RD, Heideman DA.

Cancer Prev Res (Phila). 2014 Dec;7(12):1251-7. doi: 10.1158/1940-6207.CAPR-14-0237. Epub 2014 Oct 3.

Supplemental Content

Loading ...
Support Center